Laramee P, Wonderling D, Swain S, Al-Mohammad A, Mant J. Cost-effectiveness analysis of serial measurement of circulating natriuretic peptide concentration in chronic heart failure. 192. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II 193. Ledwidge M, Barry M, Cahill J, Ryan E, Maurer B, Ryder M et al. Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care? European Journal of 194. Lee D, Wilson K, Akehurst R, Cowie MR, Zannad F, Krum H et al. Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. Heart. 2014; 195. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003; 196. Lee MC, Sulmasy DP, Gallo J, Kub J, Hughes MT, Russell S et al. Decision-making of patients with implantable cardioverter-defibrillators at end of life: Family members experiences. American Journal of Hospice & Palliative Medicine. 2017; 34(6):518-523 197. Lesogor A, Cohn JN, Latini R, Tognoni G, Krum H, Massie B et al. Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study. European Journal of 198. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006; 113(11):1424-33 199. Lewis EF, Kim HY, Claggett B, Spertus J, Heitner JF, Assmann SF et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation: 200. 